Home › Funds › Atle Fund Management AB › BBIO

Atle Fund Management AB position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Atle Fund Management AB reported holding 163,697 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$10.8M, representing 2.88% of its reported portfolio and ranking #12 among its reported holdings. Atle Fund Management AB has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)163.70K sh
Reported value held$10.77M
Portfolio Weight2.88%
First reportedQ4 2023
Last changeAdd
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Atle Fund Management AB's BBIO position evolved

Atle Fund Management AB first disclosed a stake in BBIO in Q4 2023 at 23,985 shares (US$968K). The position peaked in Q1 2026 at 111,363 shares, worth US$11.9M. Across 12 filings, Atle Fund Management AB increased the stake 8 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 163,697 shares valued at US$10.8M — an increase of 38,990 shares quarter over quarter.. Notable position changes include a 58% increase in Q1 2024 (shares fell 18% over the following quarter), a 93% increase in Q4 2024 (shares rose 26% over the following quarter), a 47% increase in Q1 2025 (shares rose 25% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 23.98K $968.27K New
Q1 2024 37.84K $1.17M Add
Q2 2024 53.43K $1.35M Add
Q3 2024 53.43K $1.36M Hold
Q4 2024 103.03K $2.81M Add
Q1 2025 151.35K $5.23M Add
Q2 2025 165.48K $7.15M Add
Q3 2025 174.72K $963.44K Add
Q4 2025 141.30K $10.81M Reduce
Q1 2026 111.36K $11.89M Reduce
Q2 2026 124.71K $9.29M Add
Q3 2026 163.70K $10.77M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 47 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Atle Fund Management AB held BBIO?

Atle Fund Management AB has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Atle Fund Management AB's current position in BBIO?

As of Q3 2026, Atle Fund Management AB holds 163.70K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $10.77M, representing 2.88% of its reported portfolio and ranking #12.

Has Atle Fund Management AB been buying or selling BBIO?

In the latest 13F filing (Q3 2026), Atle Fund Management AB increased its position in BBIO. The position peaked in Q1 2026 at 111.36K shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.